Cuprina subsidiary Cuprina Pte receives FDA 510(k) clearance for MEDIFLY Maggots wound debridement product

Cuprina Holdings (Cayman) Limited Class A

Cuprina Holdings (Cayman) Limited Class A

CUPR

0.00
  • Cuprina Pte. Ltd., an indirectly wholly owned unit of Cuprina Holdings, received U.S. FDA 510(k) clearance for MEDIFLY Maggots.
  • Clearance covers medical-grade Lucilia cuprina larvae for debridement of non-healing necrotic skin and soft-tissue wounds.
  • The unit becomes the first to secure U.S. clearance for a Lucilia cuprina maggot debridement product.
  • The group also holds U.S. commercial rights to Lucilia sericata “Medical Maggots” via a license from Ronald A. Sherman.
  • FDA clearance positions the wound-care business for U.S. rollout, with potential to support registrations in other markets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cuprina Holdings (Cayman) Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-028628), on June 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.